Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.

Date publication

septembre 2025

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine , Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Wils P, Altwegg R, Buisson A, Vuitton L, Nancey S, Richard N, Fumery M, Bouguen G, Guillo L, Caron B, Duveau N, Stefanescu C, Pelletier AL, Reenaers C, Gilletta C, Uzzan M, Arab N, Laharie D, Vidon M, Amiot A, Le Berre C, Kirchgesner J, Dewit O, Simon M, Goutorbe F, Vicaut E, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40929061

Résumé

While this strategy is frequently used for other biologics, real-world evidence on subcutaneous (SC) vedolizumab (VDZ) dose intensification in inflammatory bowel disease (IBD) is lacking. This study aimed to assess the effectiveness and safety of SC VDZ intensification.

Mots clés

dose intensification, inflammatory bowel disease, subcutaneous vedolizumab

Référence

J Crohns Colitis. 2025 09 10;: